Roche’s Tecentriq combo scoops up European approval in first-line metastatic lung cancer
pharmafile | March 8, 2019 | News story | Medical Communications, Sales and Marketing | Cancer, Europe, European Commission, NSCLC, Roche, lung cancer, pharma
Roche has announced the approval of the European Commission for its PD-L1 inhibitor Tecentriq (atezolizumab) when used in combination with Avastin (bevacizumab), paclitaxel and carboplatin as a first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC).
Further, the EC specified that this combination should only be used in patients with EGFR mutant or ALK-positive NSCLC after appropriate targeted therapies have failed.
The decision was supported by the submission of Phase 3 data drawn from 1,202 participants which demonstrated that Roche’s combo extended median overall survival by 19.8 months compared to 14.9 months with Avastin and chemotherapy alone in the intent-to-treat population. The combo also improved progression-free survival (PFS) by 41% compared to Avastin and chemotherapy, while overall response rate (ORR) stood at 56.4% of people compared to 40.2%.
“Today’s announcement makes the combination of Tecentriq, Avastin and chemotherapy available to people in Europe with advanced, non-squamous non-small cell lung cancer,” commented Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “This approval includes EGFR mutant or ALK-positive non-small cell lung cancer after failure of a targeted therapy marking a first for this subgroup of patients, in which there is a significant need for alternative treatment options.”
Matt Fellows
Related Content
Sobi’s Aspaveli receives European Commission approval for treatment of two rare kidney diseases
Sobi has announced that its Aspaveli (pegcetacoplan) has received approval from the European Commission (EC) …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
European Commission approves HIV prevention injection
The European Commission (EC) has granted marketing authorisation for Gilead Science’s Yeytuo (lenacapavir), the first …
